Inthera Bioscience

Inthera Bioscience employs a proprietary technology platform to rationally design small-molecule inhibitors targeting intracellular protein-protein interactions (PPI). The company's drug discovery programs focus on developing a new generation of first-in-class oral medications that block abnormal cellular signaling in solid tumors.